Response to Oh et al.

In the August 2005 issue of *Diabetes Care*, Oh et al. (1) reported that, in a representative population-based sample of 3,452 Korean men, cigarette smoking is associated with the metabolic syndrome. They also show a dose-dependent effect, with prevalence of the syndrome progressively increasing with the number of cigarettes smoked. Of the components of the syndrome, dyslipidemia (high triglycerides and low HDL cholesterol) and abdominal obesity are shown to be the main contributors to this association. The underlying mechanisms of this association are not explored. Insulin resistance and compensatory hyperinsulinemia are considered central features of the metabolic syndrome, yet neither factor is measured in this study.

We have explored this same issue in a large population-based sample of 2,370 nondiabetic men, aged 35–65 years, in whom the components of the metabolic syndrome, defined according to Adult Treatment Panel III criteria, were evaluated together with fasting plasma insulin; homeostasis model assessment of insulin resistance index was also calculated as a validated surrogate measure of insulin resistance.

In agreement with Oh et al., we find that chronic smoking is associated with higher triglycerides and lower HDL cholesterol with a dose effect. However, other key components of the metabolic syndrome, such as hypertension and hyperglycemia, were less common in smokers. These results were not modified after correction for BMI, alcohol and coffee consumption, and use of antihypertensive medication. Furthermore, fasting plasma insulin concentrations were very similar in smokers and never-smokers (8.02 ± 4.63 vs. 8.34 ± 3.35 μU/ml), whereas homeostasis model assessment of insulin resistance index was significantly lower in smokers (1.99 ± 1.12 vs. 2.12 ± 0.91, P < 0.01) due to the lower glucose values observed in this group.

Our data therefore confirm the finding by Oh et al. of an increased prevalence of the metabolic syndrome in smokers but suggest that this is mainly driven by higher prevalence of dyslipidemia. Furthermore, our findings expand the interpretation by providing evidence that smoking-associated dyslipidemia may be mediated by mechanisms other than insulin resistance.

**Maria Masulli, MD
Olga Vaccaro, MD**

From the Department of Clinical and Experimental Medicine, “Federico II” University of Naples, Naples, Italy.

Address correspondence to Maria Masulli, MD, Department of Clinical and Experimental Medicine, II Policlinico, Via S. Pansini 5, 80131 Napoli, Italy. E-mail: magia77@inwind.it.

© 2006 by the American Diabetes Association.

References


Association Between Cigarette Smoking and Metabolic Syndrome

Response to Masulli and Vaccaro

We thank Masulli and Vaccaro (1) for their interest and comments regarding our article (2). Moreover, we are pleased to hear that they found results similar to ours in a population-based study of Italian men. They reported that, like Korean smokers, Italian smokers had higher triglycerides and lower HDL cholesterol levels than those who had never smoked. They also showed that smoking is not associated with high fasting glucose or high blood pressure, which is similar to our findings. It is a general belief that insulin resistance is the main mechanism underlying the development of metabolic syndrome. Therefore, they tested the association between smoking and insulin resistance using the homeostasis model assessment of insulin resistance index (HOMA-IR). Contrary to their expectation, they could not find an association with HOMA-IR and they suggested that smoking-associated dyslipidemia is mediated by mechanisms other than insulin resistance.

We agree with their suggestions; however, we would like to comment on some points that must be considered. First, both their study and our own used cross-sectional observational data. As we mentioned in our article, the cross-sectional observational design has inherent limitations. Patients with type 2 diabetes and hypertension are more likely to be taking medicines that influence insulin sensitivity. Furthermore, the lifestyle, diet, and other behavioral factors that can influence insulin sensitivity may have differed. Second, HOMA-IR and fasting insulin values have an inherent limitation for predicting insulin resistance. Third, previous cohort data, which investigated temporal associations to identify causal relationships, have demonstrated that smoking increases the risks of diseases such as type 2 diabetes (3,4), which are known to have insulin resistance as their underlying mechanism. From these findings, although we agree with their suggestion, we cannot be totally confident that the association between smoking and metabolic syndrome is not mediated by insulin resistance. Further well-designed study of the temporal relationships is needed to evaluate this hypothesis.

**Sang Woo Oh, MD, PhD
Taiwoo Yoo, MD, PhD**

From the Department of Family Medicine and Center for Health Promotion, Ilsan-Paik Hospital, Inje University, College of Medicine, Gyeonggi-Do, Korea, and the Department of Family Medicine, Seoul National University, College of Medicine, Seoul, Korea.

Address correspondence to Sang Woo Oh, MD, PhD. Department of Family Medicine and Center for Health Promotion, Inje University Ilsan-paik Hospital, Daewha-Dong, Ilsan-Gu, Goyang-Si, Gyeonggi-Do, 411-706, (South) Korea. E-mail: osw6021@yahoo.co.kr.

© 2006 by the American Diabetes Association.